Jubilant Pharmova Q1 FY2023 Financial Results

Jubilant Pharmova reported financial results for Q1 FY2023 (quarter ended June 30, 2023) with ~US$783 million in annual revenue. The integrated pharmaceuticals and contract research company operates across radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, and drug discovery services with over 5,500 employees globally.